MRI contrast developer Epix Pharmaceuticals of Lexington, MA, has received clearance to market its Vasovist MR angiography agent in South Korea, the company announced.
Vasovist is an injectable intravascular contrast agent designed to provide improved imaging of the vascular system on MR angiography exams.
South Korea is the 34th country outside the U.S. where Vasovist has been approved for marketing, Epix said. The company hopes to receive clearance to market the agent in the U.S. by the end of 2008 and has recently resubmitted a new drug application to the U.S. Food and Drug Administration.
Related Reading
Epix resubmits Vasovist NDA, July 1, 2008
Epix president resigns, May 29, 2008
Epix to resubmit NDA for Vasovist, April 24, 2008
Epix reaches agreement with FDA over Vasovist, February 1, 2008
Epix to raise $16.3 million, November 12, 2007
Copyright © 2008 AuntMinnie.com
